Get the Stockscreener App
1.5136
3.67%
0.0536
Therapeuticsmd Inc stock is traded at $1.5136, with a volume of 29,737.
It is up +3.67% in the last 24 hours and up +52.89% over the past month.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
See More
Previous Close:
$1.46
Open:
$1.42
24h Volume:
29,737
Relative Volume:
0.11
Market Cap:
$17.51M
Revenue:
$996.00K
Net Income/Loss:
$-6.09M
P/E Ratio:
-2.8558
EPS:
-0.53
Net Cash Flow:
$-9.76M
1W Performance:
+3.67%
1M Performance:
+52.89%
6M Performance:
+8.11%
1Y Performance:
-28.60%
1-Day Range:
$1.42
$1.52
1-Week Range:
$1.40
$1.54
52-Week Range:
$0.70
$2.44
Therapeuticsmd Inc Stock (TXMD) Company Profile
Name
Therapeuticsmd Inc
Sector
Phone
561-961-1900
Address
951 YAMATO ROAD, SUITE 220, BOCA RATON, FL
Compare TXMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TXMD
Therapeuticsmd Inc
|
1.5136 | 16.20M | 996.00K | -6.09M | -9.76M | -0.53 |
|
HLN
Haleon Plc Adr
|
10.71 | 47.63B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
162.35 | 71.99B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.7763 | 3.50M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.03 | 44.91B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.87 | 20.73B | 16.54B | -1.64B | 749.00M | -1.45 |
Therapeuticsmd Inc Stock (TXMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-07-20 | Downgrade | Jefferies | Hold → Underperform |
| May-19-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-02-19 | Initiated | Guggenheim | Buy |
| Oct-17-19 | Initiated | H.C. Wainwright | Buy |
| Apr-30-19 | Resumed | Noble Capital Markets | Outperform |
| Jun-15-18 | Initiated | JP Morgan | Overweight |
| Sep-08-17 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-11-17 | Upgrade | Oppenheimer | Perform → Outperform |
| May-09-17 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-22-16 | Resumed | Jefferies | Buy |
| Nov-22-16 | Initiated | Oppenheimer | Outperform |
| Nov-07-16 | Resumed | Guggenheim | Buy |
| Apr-04-16 | Initiated | Goldman | Buy |
| Dec-08-15 | Reiterated | Jefferies | Buy |
| Dec-08-15 | Reiterated | Stifel | Buy |
| Sep-21-15 | Reiterated | Jefferies | Buy |
| Jun-09-15 | Initiated | Guggenheim | Buy |
| Jul-08-14 | Initiated | FBR Capital | Outperform |
| Apr-17-14 | Reiterated | Noble Financial | Buy |
| Jan-28-14 | Reiterated | Noble Financial | Buy |
View All
Therapeuticsmd Inc Stock (TXMD) Latest News
TherapeuticsMD (NASDAQ:TXMD) Now Covered by Analysts at StockNews.com - Defense World
TherapeuticsMD Reports Improved Q1 2025 Results - TipRanks
TherapeuticsMD Announces First Quarter 2025 Financial Results | - GuruFocus
TherapeuticsMD: Q1 Earnings Snapshot - CT Insider
TherapeuticsMD Announces First Quarter 2025 Financial Results - BioSpace
TherapeuticsMD Inc Reports Q1 2025 Results: EPS at -$0.06, Reven - GuruFocus
TherapeuticsMD Reports Q1 2025 Financial Results - TipRanks
TherapeuticsMD Q1 Operating Expenses USD 1.264 Million - marketscreener.com
TherapeuticsMD (NASDAQ:TXMD) Research Coverage Started at StockNews.com - Defense World
Today's Dead Cat Bounce Stock: TherapeuticsMD (TXMD) - TheStreet
StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD) - Defense World
TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch
Press Release Distribution & PR Platform - ACCESS Newswire
TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
TherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.com - Defense World
TherapeuticsMD Inc. stock outperforms competitors despite losses on the day - MarketWatch
TherapeuticsMD CEO Marlan Walker acquires $489 in common stock By Investing.com - Investing.com Canada
TherapeuticsMD director Tommy Thompson acquires $325 in stock - Investing.com Australia
TherapeuticsMD director Tommy Thompson acquires $325 in stock By Investing.com - Investing.com Canada
TherapeuticsMD CEO Marlan Walker acquires $489 in common stock - Investing.com
TherapeuticsMD CEO Marlan Walker buys $489 in common stock By Investing.com - Investing.com South Africa
TherapeuticsMD CEO Marlan Walker buys $489 in common stock - Investing.com
INVESTOR ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Reminds Investors with Losses to Contact the Firm - ACCESS Newswire
DEADLINE TODAY: Lundin Law PC Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Reminds Investors with Losses to Contact the Firm - ACCESS Newswire
Mayne Pharma Faces Legal Challenge from TherapeuticsMD - TipRanks
TherapeuticsMD CEO Marlan Walker buys $1,994 in stock - Investing.com Australia
TherapeuticsMD CEO Marlan Walker buys $1,994 in stock By Investing.com - Investing.com India
TherapeuticsMD Inc. stock rises Wednesday, still underperforms market - MarketWatch
TherapeuticsmdFiles Lawsuit Against Mayne Pharma For Breach Of Contract - marketscreener.com
TherapeuticsMD Inc. stock underperforms Friday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Therapeuticsmd Inc Stock (TXMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Therapeuticsmd Inc Stock (TXMD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Walker Marlan D | Chief Executive Officer |
Apr 14 '25 |
Buy |
1.00 |
490 |
489 |
73,639 |
| Walker Marlan D | Chief Executive Officer |
Apr 10 '25 |
Buy |
0.86 |
1,167 |
1,000 |
73,149 |
| Walker Marlan D | Chief Executive Officer |
Apr 09 '25 |
Buy |
0.87 |
1,136 |
994 |
71,982 |
| Collins Cooper C. | Director |
Feb 18 '25 |
Option Exercise |
0.00 |
8,500 |
0 |
60,516 |
| Naughton Gail K | Director |
Feb 18 '25 |
Option Exercise |
0.00 |
8,500 |
0 |
8,500 |
| Thompson Tommy G | Director |
Feb 18 '25 |
Option Exercise |
0.00 |
8,500 |
0 |
14,454 |
| Walker Marlan D | Chief Executive Officer |
Feb 18 '25 |
Option Exercise |
0.00 |
8,281 |
0 |
70,846 |
| Collins Cooper C. | Director |
Aug 22 '24 |
Buy |
1.73 |
4,094 |
7,099 |
52,016 |
| Collins Cooper C. | Director |
Aug 21 '24 |
Buy |
1.70 |
1,200 |
2,039 |
47,922 |
0.28%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):